nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—GJA1—prostate cancer	0.163	0.381	CbGaD
Carvedilol—HIF1A—prostate cancer	0.124	0.289	CbGaD
Carvedilol—VEGFA—prostate cancer	0.0498	0.116	CbGaD
Carvedilol—ADRB2—prostate cancer	0.028	0.0654	CbGaD
Carvedilol—CYP2E1—prostate cancer	0.0244	0.0569	CbGaD
Carvedilol—CYP1A1—prostate cancer	0.024	0.0561	CbGaD
Carvedilol—CYP1A1—Flutamide—prostate cancer	0.0219	0.0784	CbGbCtD
Carvedilol—CYP1A1—Estrone—prostate cancer	0.0158	0.0567	CbGbCtD
Carvedilol—CYP3A4—prostate cancer	0.0153	0.0358	CbGaD
Carvedilol—XDH—Doxorubicin—prostate cancer	0.0139	0.0497	CbGbCtD
Carvedilol—CYP2E1—Estrone—prostate cancer	0.0122	0.0438	CbGbCtD
Carvedilol—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0118	0.0421	CbGbCtD
Carvedilol—CYP2C9—Nilutamide—prostate cancer	0.0106	0.0381	CbGbCtD
Carvedilol—CYP2C9—Bicalutamide—prostate cancer	0.0106	0.0381	CbGbCtD
Carvedilol—CYP1A2—Flutamide—prostate cancer	0.00977	0.035	CbGbCtD
Carvedilol—CYP2D6—Bicalutamide—prostate cancer	0.00972	0.0348	CbGbCtD
Carvedilol—ABCB1—Estramustine—prostate cancer	0.00959	0.0344	CbGbCtD
Carvedilol—CYP1A1—Estradiol—prostate cancer	0.00909	0.0325	CbGbCtD
Carvedilol—CYP2D6—Abiraterone—prostate cancer	0.00805	0.0288	CbGbCtD
Carvedilol—CYP2E1—Mitoxantrone—prostate cancer	0.00727	0.026	CbGbCtD
Carvedilol—CYP1A2—Estrone—prostate cancer	0.00707	0.0253	CbGbCtD
Carvedilol—ADRA1B—vas deferens—prostate cancer	0.00681	0.122	CbGeAlD
Carvedilol—CYP2C9—Estrone—prostate cancer	0.00637	0.0228	CbGbCtD
Carvedilol—ABCB1—Cabazitaxel—prostate cancer	0.00632	0.0226	CbGbCtD
Carvedilol—CYP3A4—Bicalutamide—prostate cancer	0.00618	0.0221	CbGbCtD
Carvedilol—ABCB1—Estrone—prostate cancer	0.00618	0.0221	CbGbCtD
Carvedilol—PTGS1—Etoposide—prostate cancer	0.00593	0.0213	CbGbCtD
Carvedilol—CYP3A4—Estramustine—prostate cancer	0.00575	0.0206	CbGbCtD
Carvedilol—ABCB1—Ethinyl Estradiol—prostate cancer	0.00551	0.0197	CbGbCtD
Carvedilol—CYP3A4—Abiraterone—prostate cancer	0.00512	0.0183	CbGbCtD
Carvedilol—CYP3A4—Flutamide—prostate cancer	0.00512	0.0183	CbGbCtD
Carvedilol—CYP2C9—Capecitabine—prostate cancer	0.00483	0.0173	CbGbCtD
Carvedilol—CYP1A2—Conjugated Estrogens—prostate cancer	0.00462	0.0166	CbGbCtD
Carvedilol—CYP2E1—Etoposide—prostate cancer	0.00458	0.0164	CbGbCtD
Carvedilol—CYP1A2—Estradiol—prostate cancer	0.00406	0.0145	CbGbCtD
Carvedilol—ABCB1—Conjugated Estrogens—prostate cancer	0.00404	0.0145	CbGbCtD
Carvedilol—CYP3A4—Cabazitaxel—prostate cancer	0.00379	0.0136	CbGbCtD
Carvedilol—CYP3A4—Estrone—prostate cancer	0.0037	0.0133	CbGbCtD
Carvedilol—ABCB1—Mitoxantrone—prostate cancer	0.00367	0.0132	CbGbCtD
Carvedilol—CYP2C9—Estradiol—prostate cancer	0.00366	0.0131	CbGbCtD
Carvedilol—ABCB1—Estradiol—prostate cancer	0.00355	0.0127	CbGbCtD
Carvedilol—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0033	0.0118	CbGbCtD
Carvedilol—ABCB1—Prednisone—prostate cancer	0.00305	0.0109	CbGbCtD
Carvedilol—CYP1A2—Etoposide—prostate cancer	0.00265	0.00949	CbGbCtD
Carvedilol—CYP3A4—Conjugated Estrogens—prostate cancer	0.00242	0.00868	CbGbCtD
Carvedilol—ABCB1—Etoposide—prostate cancer	0.00232	0.0083	CbGbCtD
Carvedilol—CYP3A4—Mitoxantrone—prostate cancer	0.0022	0.00789	CbGbCtD
Carvedilol—CYP3A4—Estradiol—prostate cancer	0.00213	0.00762	CbGbCtD
Carvedilol—ABCB1—Docetaxel—prostate cancer	0.00212	0.0076	CbGbCtD
Carvedilol—CYP3A4—Prednisone—prostate cancer	0.00183	0.00655	CbGbCtD
Carvedilol—ABCB1—Doxorubicin—prostate cancer	0.00158	0.00566	CbGbCtD
Carvedilol—CYP2D6—Doxorubicin—prostate cancer	0.00149	0.00534	CbGbCtD
Carvedilol—CYP3A4—Etoposide—prostate cancer	0.00139	0.00497	CbGbCtD
Carvedilol—SELE—prostate gland—prostate cancer	0.00134	0.024	CbGeAlD
Carvedilol—CYP3A4—Docetaxel—prostate cancer	0.00127	0.00455	CbGbCtD
Carvedilol—VCAM1—prostate gland—prostate cancer	0.00123	0.0221	CbGeAlD
Carvedilol—HIF1A—prostate gland—prostate cancer	0.00119	0.0212	CbGeAlD
Carvedilol—GJA1—prostate gland—prostate cancer	0.00115	0.0206	CbGeAlD
Carvedilol—SELE—seminal vesicle—prostate cancer	0.00114	0.0203	CbGeAlD
Carvedilol—ADRB3—prostate gland—prostate cancer	0.00106	0.0189	CbGeAlD
Carvedilol—VCAM1—seminal vesicle—prostate cancer	0.00104	0.0187	CbGeAlD
Carvedilol—HIF1A—seminal vesicle—prostate cancer	0.001	0.0179	CbGeAlD
Carvedilol—NDUFC2—prostate gland—prostate cancer	0.001	0.0179	CbGeAlD
Carvedilol—SELE—epithelium—prostate cancer	0.000987	0.0176	CbGeAlD
Carvedilol—GJA1—seminal vesicle—prostate cancer	0.000975	0.0174	CbGeAlD
Carvedilol—CYP3A4—Doxorubicin—prostate cancer	0.000947	0.00339	CbGbCtD
Carvedilol—SELE—renal system—prostate cancer	0.000915	0.0163	CbGeAlD
Carvedilol—VEGFA—prostate gland—prostate cancer	0.00091	0.0163	CbGeAlD
Carvedilol—VCAM1—epithelium—prostate cancer	0.000907	0.0162	CbGeAlD
Carvedilol—SELE—urethra—prostate cancer	0.000899	0.0161	CbGeAlD
Carvedilol—HIF1A—epithelium—prostate cancer	0.000873	0.0156	CbGeAlD
Carvedilol—NDUFC2—seminal vesicle—prostate cancer	0.000849	0.0152	CbGeAlD
Carvedilol—GJA1—epithelium—prostate cancer	0.000847	0.0151	CbGeAlD
Carvedilol—VCAM1—renal system—prostate cancer	0.000842	0.015	CbGeAlD
Carvedilol—VCAM1—urethra—prostate cancer	0.000827	0.0148	CbGeAlD
Carvedilol—XDH—prostate gland—prostate cancer	0.00081	0.0145	CbGeAlD
Carvedilol—HIF1A—renal system—prostate cancer	0.00081	0.0145	CbGeAlD
Carvedilol—HIF1A—urethra—prostate cancer	0.000796	0.0142	CbGeAlD
Carvedilol—CYP1A2—urine—prostate cancer	0.000787	0.014	CbGeAlD
Carvedilol—GJA1—renal system—prostate cancer	0.000786	0.014	CbGeAlD
Carvedilol—GJA1—urethra—prostate cancer	0.000772	0.0138	CbGeAlD
Carvedilol—CYP2C9—urine—prostate cancer	0.000747	0.0133	CbGeAlD
Carvedilol—NDUFC2—epithelium—prostate cancer	0.000737	0.0132	CbGeAlD
Carvedilol—CYP2E1—urine—prostate cancer	0.000708	0.0126	CbGeAlD
Carvedilol—NDUFC2—renal system—prostate cancer	0.000684	0.0122	CbGeAlD
Carvedilol—NDUFC2—urethra—prostate cancer	0.000672	0.012	CbGeAlD
Carvedilol—VCAM1—bone marrow—prostate cancer	0.000636	0.0114	CbGeAlD
Carvedilol—HIF1A—bone marrow—prostate cancer	0.000612	0.0109	CbGeAlD
Carvedilol—VEGFA—urethra—prostate cancer	0.000609	0.0109	CbGeAlD
Carvedilol—ADRA1D—prostate gland—prostate cancer	0.000595	0.0106	CbGeAlD
Carvedilol—GJA1—bone marrow—prostate cancer	0.000594	0.0106	CbGeAlD
Carvedilol—SELE—testis—prostate cancer	0.000591	0.0106	CbGeAlD
Carvedilol—CYP3A4—urine—prostate cancer	0.000569	0.0102	CbGeAlD
Carvedilol—CYP2D6—urine—prostate cancer	0.00056	0.01	CbGeAlD
Carvedilol—XDH—renal system—prostate cancer	0.000552	0.00986	CbGeAlD
Carvedilol—VCAM1—testis—prostate cancer	0.000544	0.00971	CbGeAlD
Carvedilol—HIF1A—testis—prostate cancer	0.000523	0.00935	CbGeAlD
Carvedilol—NDUFC2—bone marrow—prostate cancer	0.000517	0.00923	CbGeAlD
Carvedilol—GJA1—testis—prostate cancer	0.000508	0.00907	CbGeAlD
Carvedilol—VEGFA—bone marrow—prostate cancer	0.000469	0.00837	CbGeAlD
Carvedilol—NDUFC2—testis—prostate cancer	0.000442	0.00789	CbGeAlD
Carvedilol—ADRA1D—epithelium—prostate cancer	0.000437	0.0078	CbGeAlD
Carvedilol—ADRB1—prostate gland—prostate cancer	0.000432	0.00771	CbGeAlD
Carvedilol—SELE—lymph node—prostate cancer	0.000429	0.00765	CbGeAlD
Carvedilol—ADRA1B—renal system—prostate cancer	0.000414	0.0074	CbGeAlD
Carvedilol—VEGFA—testis—prostate cancer	0.000401	0.00716	CbGeAlD
Carvedilol—ADRA1D—urethra—prostate cancer	0.000398	0.00711	CbGeAlD
Carvedilol—VCAM1—lymph node—prostate cancer	0.000394	0.00704	CbGeAlD
Carvedilol—HIF1A—lymph node—prostate cancer	0.000379	0.00677	CbGeAlD
Carvedilol—VEGFA—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000373	0.19	CbGdCrCtD
Carvedilol—GJA1—lymph node—prostate cancer	0.000368	0.00657	CbGeAlD
Carvedilol—ADRA1A—prostate gland—prostate cancer	0.000342	0.0061	CbGeAlD
Carvedilol—KCNH2—prostate gland—prostate cancer	0.00033	0.00589	CbGeAlD
Carvedilol—ADRA2C—prostate gland—prostate cancer	0.000325	0.00581	CbGeAlD
Carvedilol—NDUFC2—lymph node—prostate cancer	0.00032	0.00572	CbGeAlD
Carvedilol—VEGFA—Estradiol—Estramustine—prostate cancer	0.000317	0.162	CbGdCrCtD
Carvedilol—VEGFA—lymph node—prostate cancer	0.000291	0.00519	CbGeAlD
Carvedilol—KCNH2—seminal vesicle—prostate cancer	0.000279	0.00498	CbGeAlD
Carvedilol—ADRA2C—seminal vesicle—prostate cancer	0.000275	0.00491	CbGeAlD
Carvedilol—GJA1—Cortisone acetate—Prednisone—prostate cancer	0.000271	0.138	CbGdCrCtD
Carvedilol—ADRA2A—prostate gland—prostate cancer	0.00026	0.00464	CbGeAlD
Carvedilol—Bevantolol—ADRB2—prostate cancer	0.000254	0.21	CrCbGaD
Carvedilol—CYP2E1—prostate gland—prostate cancer	0.000254	0.00454	CbGeAlD
Carvedilol—VEGFA—Estradiol—Estrone—prostate cancer	0.000252	0.129	CbGdCrCtD
Carvedilol—ADRA1A—epithelium—prostate cancer	0.000251	0.00448	CbGeAlD
Carvedilol—PTGS1—prostate gland—prostate cancer	0.000245	0.00437	CbGeAlD
Carvedilol—Bopindolol—ADRB2—prostate cancer	0.000235	0.194	CrCbGaD
Carvedilol—ADRA1A—renal system—prostate cancer	0.000233	0.00416	CbGeAlD
Carvedilol—KCNH2—renal system—prostate cancer	0.000225	0.00401	CbGeAlD
Carvedilol—ADRA2C—renal system—prostate cancer	0.000222	0.00396	CbGeAlD
Carvedilol—VEGFA—Estradiol—Conjugated Estrogens—prostate cancer	0.000222	0.113	CbGdCrCtD
Carvedilol—KCNH2—urethra—prostate cancer	0.000221	0.00394	CbGeAlD
Carvedilol—ADRA2A—seminal vesicle—prostate cancer	0.00022	0.00392	CbGeAlD
Carvedilol—ADRA2C—urethra—prostate cancer	0.000218	0.00389	CbGeAlD
Carvedilol—CYP2E1—seminal vesicle—prostate cancer	0.000215	0.00384	CbGeAlD
Carvedilol—PTGS1—seminal vesicle—prostate cancer	0.000207	0.0037	CbGeAlD
Carvedilol—CYP1A1—epithelium—prostate cancer	0.000205	0.00365	CbGeAlD
Carvedilol—CYP1A2—renal system—prostate cancer	0.000192	0.00344	CbGeAlD
Carvedilol—CYP1A1—renal system—prostate cancer	0.00019	0.00339	CbGeAlD
Carvedilol—CYP1A1—urethra—prostate cancer	0.000186	0.00333	CbGeAlD
Carvedilol—VEGFA—Estradiol—Ethinyl Estradiol—prostate cancer	0.000186	0.0951	CbGdCrCtD
Carvedilol—GJA1—Rimexolone—Prednisone—prostate cancer	0.000182	0.0932	CbGdCrCtD
Carvedilol—PTGS1—epithelium—prostate cancer	0.00018	0.00321	CbGeAlD
Carvedilol—ADRA2A—urethra—prostate cancer	0.000174	0.0031	CbGeAlD
Carvedilol—CYP2E1—renal system—prostate cancer	0.000173	0.00309	CbGeAlD
Carvedilol—CYP2E1—urethra—prostate cancer	0.00017	0.00304	CbGeAlD
Carvedilol—KCNH2—bone marrow—prostate cancer	0.00017	0.00303	CbGeAlD
Carvedilol—PTGS1—renal system—prostate cancer	0.000167	0.00298	CbGeAlD
Carvedilol—KCNH2—testis—prostate cancer	0.000145	0.00259	CbGeAlD
Carvedilol—ABCB1—prostate gland—prostate cancer	0.000145	0.00258	CbGeAlD
Carvedilol—ADRA2C—testis—prostate cancer	0.000143	0.00256	CbGeAlD
Carvedilol—CYP3A4—renal system—prostate cancer	0.000139	0.00249	CbGeAlD
Carvedilol—CYP2D6—renal system—prostate cancer	0.000137	0.00245	CbGeAlD
Carvedilol—Ranolazine—CYP3A4—prostate cancer	0.000129	0.106	CrCbGaD
Carvedilol—Tamsulosin—CYP3A4—prostate cancer	0.000124	0.102	CrCbGaD
Carvedilol—ABCB1—seminal vesicle—prostate cancer	0.000122	0.00219	CbGeAlD
Carvedilol—ADRA2A—testis—prostate cancer	0.000114	0.00204	CbGeAlD
Carvedilol—CYP2E1—testis—prostate cancer	0.000112	0.002	CbGeAlD
Carvedilol—Propranolol—CYP3A5—prostate cancer	0.000112	0.0921	CrCbGaD
Carvedilol—PTGS1—testis—prostate cancer	0.000108	0.00192	CbGeAlD
Carvedilol—ABCB1—epithelium—prostate cancer	0.000106	0.0019	CbGeAlD
Carvedilol—KCNH2—lymph node—prostate cancer	0.000105	0.00188	CbGeAlD
Carvedilol—ADRA2C—lymph node—prostate cancer	0.000104	0.00186	CbGeAlD
Carvedilol—ABCB1—renal system—prostate cancer	9.86e-05	0.00176	CbGeAlD
Carvedilol—ABCB1—urethra—prostate cancer	9.69e-05	0.00173	CbGeAlD
Carvedilol—CYP1A1—lymph node—prostate cancer	8.89e-05	0.00159	CbGeAlD
Carvedilol—CYP2D6—testis—prostate cancer	8.86e-05	0.00158	CbGeAlD
Carvedilol—Propranolol—ADRB2—prostate cancer	8.83e-05	0.0728	CrCbGaD
Carvedilol—ADRA2A—lymph node—prostate cancer	8.29e-05	0.00148	CbGeAlD
Carvedilol—PTGS1—lymph node—prostate cancer	7.81e-05	0.0014	CbGeAlD
Carvedilol—Propranolol—CYP2C19—prostate cancer	7.6e-05	0.0627	CrCbGaD
Carvedilol—Propranolol—CYP1A1—prostate cancer	7.57e-05	0.0624	CrCbGaD
Carvedilol—ABCB1—bone marrow—prostate cancer	7.46e-05	0.00133	CbGeAlD
Carvedilol—Propafenone—CYP3A4—prostate cancer	7.06e-05	0.0582	CrCbGaD
Carvedilol—ABCB1—testis—prostate cancer	6.37e-05	0.00114	CbGeAlD
Carvedilol—Propranolol—CYP3A4—prostate cancer	4.83e-05	0.0399	CrCbGaD
Carvedilol—ABCB1—lymph node—prostate cancer	4.62e-05	0.000825	CbGeAlD
Carvedilol—GJA1—Dexamethasone—Prednisone—prostate cancer	4.13e-05	0.0211	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Prednisone—prostate cancer	4.13e-05	0.0211	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Prednisone—prostate cancer	3.64e-05	0.0186	CbGdCrCtD
Carvedilol—VEGFA—Dexamethasone—Prednisone—prostate cancer	3.64e-05	0.0186	CbGdCrCtD
Carvedilol—Anorexia—Capecitabine—prostate cancer	2.23e-05	0.00018	CcSEcCtD
Carvedilol—Nausea—Estradiol—prostate cancer	2.23e-05	0.00018	CcSEcCtD
Carvedilol—Vomiting—Mitoxantrone—prostate cancer	2.22e-05	0.000179	CcSEcCtD
Carvedilol—Sinusitis—Doxorubicin—prostate cancer	2.22e-05	0.000179	CcSEcCtD
Carvedilol—Convulsion—Prednisone—prostate cancer	2.21e-05	0.000179	CcSEcCtD
Carvedilol—Visual impairment—Epirubicin—prostate cancer	2.21e-05	0.000179	CcSEcCtD
Carvedilol—Hypertension—Prednisone—prostate cancer	2.2e-05	0.000178	CcSEcCtD
Carvedilol—Rash—Mitoxantrone—prostate cancer	2.2e-05	0.000178	CcSEcCtD
Carvedilol—Dermatitis—Mitoxantrone—prostate cancer	2.2e-05	0.000178	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Docetaxel—prostate cancer	2.2e-05	0.000178	CcSEcCtD
Carvedilol—Headache—Mitoxantrone—prostate cancer	2.19e-05	0.000177	CcSEcCtD
Carvedilol—Hypotension—Capecitabine—prostate cancer	2.18e-05	0.000177	CcSEcCtD
Carvedilol—Insomnia—Docetaxel—prostate cancer	2.18e-05	0.000176	CcSEcCtD
Carvedilol—Myalgia—Prednisone—prostate cancer	2.17e-05	0.000176	CcSEcCtD
Carvedilol—Arthralgia—Prednisone—prostate cancer	2.17e-05	0.000176	CcSEcCtD
Carvedilol—Paraesthesia—Docetaxel—prostate cancer	2.17e-05	0.000175	CcSEcCtD
Carvedilol—Erythema multiforme—Epirubicin—prostate cancer	2.17e-05	0.000175	CcSEcCtD
Carvedilol—Bradycardia—Doxorubicin—prostate cancer	2.16e-05	0.000175	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.16e-05	0.000174	CcSEcCtD
Carvedilol—Dyspnoea—Docetaxel—prostate cancer	2.15e-05	0.000174	CcSEcCtD
Carvedilol—Somnolence—Docetaxel—prostate cancer	2.15e-05	0.000173	CcSEcCtD
Carvedilol—Discomfort—Prednisone—prostate cancer	2.14e-05	0.000173	CcSEcCtD
Carvedilol—Hypersensitivity—Etoposide—prostate cancer	2.14e-05	0.000173	CcSEcCtD
Carvedilol—Tinnitus—Epirubicin—prostate cancer	2.14e-05	0.000173	CcSEcCtD
Carvedilol—Haemoglobin—Doxorubicin—prostate cancer	2.13e-05	0.000172	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.13e-05	0.000172	CcSEcCtD
Carvedilol—Rhinitis—Doxorubicin—prostate cancer	2.13e-05	0.000172	CcSEcCtD
Carvedilol—Dyspepsia—Docetaxel—prostate cancer	2.12e-05	0.000172	CcSEcCtD
Carvedilol—Haemorrhage—Doxorubicin—prostate cancer	2.12e-05	0.000171	CcSEcCtD
Carvedilol—Insomnia—Capecitabine—prostate cancer	2.11e-05	0.000171	CcSEcCtD
Carvedilol—Hypoaesthesia—Doxorubicin—prostate cancer	2.11e-05	0.000171	CcSEcCtD
Carvedilol—Pharyngitis—Doxorubicin—prostate cancer	2.1e-05	0.00017	CcSEcCtD
Carvedilol—Paraesthesia—Capecitabine—prostate cancer	2.1e-05	0.00017	CcSEcCtD
Carvedilol—Decreased appetite—Docetaxel—prostate cancer	2.1e-05	0.00017	CcSEcCtD
Carvedilol—Urinary tract disorder—Doxorubicin—prostate cancer	2.09e-05	0.000169	CcSEcCtD
Carvedilol—Oedema peripheral—Doxorubicin—prostate cancer	2.09e-05	0.000169	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Docetaxel—prostate cancer	2.08e-05	0.000168	CcSEcCtD
Carvedilol—Asthenia—Etoposide—prostate cancer	2.08e-05	0.000168	CcSEcCtD
Carvedilol—Dyspnoea—Capecitabine—prostate cancer	2.08e-05	0.000168	CcSEcCtD
Carvedilol—Oedema—Prednisone—prostate cancer	2.08e-05	0.000168	CcSEcCtD
Carvedilol—Anaphylactic shock—Prednisone—prostate cancer	2.08e-05	0.000168	CcSEcCtD
Carvedilol—Fatigue—Docetaxel—prostate cancer	2.08e-05	0.000168	CcSEcCtD
Carvedilol—Angiopathy—Epirubicin—prostate cancer	2.08e-05	0.000168	CcSEcCtD
Carvedilol—Urethral disorder—Doxorubicin—prostate cancer	2.08e-05	0.000168	CcSEcCtD
Carvedilol—Nausea—Mitoxantrone—prostate cancer	2.07e-05	0.000168	CcSEcCtD
Carvedilol—Immune system disorder—Epirubicin—prostate cancer	2.07e-05	0.000167	CcSEcCtD
Carvedilol—Infection—Prednisone—prostate cancer	2.07e-05	0.000167	CcSEcCtD
Carvedilol—Mediastinal disorder—Epirubicin—prostate cancer	2.06e-05	0.000167	CcSEcCtD
Carvedilol—Constipation—Docetaxel—prostate cancer	2.06e-05	0.000167	CcSEcCtD
Carvedilol—Pain—Docetaxel—prostate cancer	2.06e-05	0.000167	CcSEcCtD
Carvedilol—Dyspepsia—Capecitabine—prostate cancer	2.06e-05	0.000166	CcSEcCtD
Carvedilol—Pruritus—Etoposide—prostate cancer	2.05e-05	0.000166	CcSEcCtD
Carvedilol—Shock—Prednisone—prostate cancer	2.05e-05	0.000166	CcSEcCtD
Carvedilol—Visual impairment—Doxorubicin—prostate cancer	2.04e-05	0.000165	CcSEcCtD
Carvedilol—Tachycardia—Prednisone—prostate cancer	2.03e-05	0.000164	CcSEcCtD
Carvedilol—Decreased appetite—Capecitabine—prostate cancer	2.03e-05	0.000164	CcSEcCtD
Carvedilol—Alopecia—Epirubicin—prostate cancer	2.02e-05	0.000164	CcSEcCtD
Carvedilol—Skin disorder—Prednisone—prostate cancer	2.02e-05	0.000163	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Capecitabine—prostate cancer	2.02e-05	0.000163	CcSEcCtD
Carvedilol—Fatigue—Capecitabine—prostate cancer	2.01e-05	0.000163	CcSEcCtD
Carvedilol—Hyperhidrosis—Prednisone—prostate cancer	2.01e-05	0.000163	CcSEcCtD
Carvedilol—Erythema multiforme—Doxorubicin—prostate cancer	2e-05	0.000162	CcSEcCtD
Carvedilol—Pain—Capecitabine—prostate cancer	2e-05	0.000162	CcSEcCtD
Carvedilol—Constipation—Capecitabine—prostate cancer	2e-05	0.000162	CcSEcCtD
Carvedilol—Malnutrition—Epirubicin—prostate cancer	1.99e-05	0.000161	CcSEcCtD
Carvedilol—Feeling abnormal—Docetaxel—prostate cancer	1.99e-05	0.000161	CcSEcCtD
Carvedilol—Diarrhoea—Etoposide—prostate cancer	1.99e-05	0.000161	CcSEcCtD
Carvedilol—Anorexia—Prednisone—prostate cancer	1.98e-05	0.00016	CcSEcCtD
Carvedilol—Tinnitus—Doxorubicin—prostate cancer	1.98e-05	0.00016	CcSEcCtD
Carvedilol—Gastrointestinal pain—Docetaxel—prostate cancer	1.97e-05	0.00016	CcSEcCtD
Carvedilol—Flatulence—Epirubicin—prostate cancer	1.97e-05	0.000159	CcSEcCtD
Carvedilol—Tension—Epirubicin—prostate cancer	1.96e-05	0.000158	CcSEcCtD
Carvedilol—Nervousness—Epirubicin—prostate cancer	1.94e-05	0.000157	CcSEcCtD
Carvedilol—Back pain—Epirubicin—prostate cancer	1.93e-05	0.000156	CcSEcCtD
Carvedilol—Feeling abnormal—Capecitabine—prostate cancer	1.93e-05	0.000156	CcSEcCtD
Carvedilol—Angiopathy—Doxorubicin—prostate cancer	1.92e-05	0.000156	CcSEcCtD
Carvedilol—Dizziness—Etoposide—prostate cancer	1.92e-05	0.000155	CcSEcCtD
Carvedilol—Muscle spasms—Epirubicin—prostate cancer	1.92e-05	0.000155	CcSEcCtD
Carvedilol—Immune system disorder—Doxorubicin—prostate cancer	1.91e-05	0.000155	CcSEcCtD
Carvedilol—Gastrointestinal pain—Capecitabine—prostate cancer	1.91e-05	0.000154	CcSEcCtD
Carvedilol—Mediastinal disorder—Doxorubicin—prostate cancer	1.91e-05	0.000154	CcSEcCtD
Carvedilol—Body temperature increased—Docetaxel—prostate cancer	1.91e-05	0.000154	CcSEcCtD
Carvedilol—Abdominal pain—Docetaxel—prostate cancer	1.91e-05	0.000154	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Prednisone—prostate cancer	1.9e-05	0.000153	CcSEcCtD
Carvedilol—Insomnia—Prednisone—prostate cancer	1.88e-05	0.000152	CcSEcCtD
Carvedilol—Vision blurred—Epirubicin—prostate cancer	1.88e-05	0.000152	CcSEcCtD
Carvedilol—Alopecia—Doxorubicin—prostate cancer	1.87e-05	0.000151	CcSEcCtD
Carvedilol—Paraesthesia—Prednisone—prostate cancer	1.87e-05	0.000151	CcSEcCtD
Carvedilol—Urticaria—Capecitabine—prostate cancer	1.86e-05	0.00015	CcSEcCtD
Carvedilol—Ill-defined disorder—Epirubicin—prostate cancer	1.85e-05	0.00015	CcSEcCtD
Carvedilol—Body temperature increased—Capecitabine—prostate cancer	1.85e-05	0.000149	CcSEcCtD
Carvedilol—Abdominal pain—Capecitabine—prostate cancer	1.85e-05	0.000149	CcSEcCtD
Carvedilol—Vomiting—Etoposide—prostate cancer	1.85e-05	0.000149	CcSEcCtD
Carvedilol—Malnutrition—Doxorubicin—prostate cancer	1.85e-05	0.000149	CcSEcCtD
Carvedilol—Anaemia—Epirubicin—prostate cancer	1.84e-05	0.000149	CcSEcCtD
Carvedilol—Dyspepsia—Prednisone—prostate cancer	1.83e-05	0.000148	CcSEcCtD
Carvedilol—Rash—Etoposide—prostate cancer	1.83e-05	0.000148	CcSEcCtD
Carvedilol—Dermatitis—Etoposide—prostate cancer	1.83e-05	0.000148	CcSEcCtD
Carvedilol—Headache—Etoposide—prostate cancer	1.82e-05	0.000147	CcSEcCtD
Carvedilol—Flatulence—Doxorubicin—prostate cancer	1.82e-05	0.000147	CcSEcCtD
Carvedilol—Tension—Doxorubicin—prostate cancer	1.81e-05	0.000146	CcSEcCtD
Carvedilol—Decreased appetite—Prednisone—prostate cancer	1.81e-05	0.000146	CcSEcCtD
Carvedilol—Malaise—Epirubicin—prostate cancer	1.8e-05	0.000145	CcSEcCtD
Carvedilol—Fatigue—Prednisone—prostate cancer	1.79e-05	0.000145	CcSEcCtD
Carvedilol—Nervousness—Doxorubicin—prostate cancer	1.79e-05	0.000145	CcSEcCtD
Carvedilol—Vertigo—Epirubicin—prostate cancer	1.79e-05	0.000145	CcSEcCtD
Carvedilol—Syncope—Epirubicin—prostate cancer	1.79e-05	0.000145	CcSEcCtD
Carvedilol—Leukopenia—Epirubicin—prostate cancer	1.79e-05	0.000144	CcSEcCtD
Carvedilol—Back pain—Doxorubicin—prostate cancer	1.78e-05	0.000144	CcSEcCtD
Carvedilol—Constipation—Prednisone—prostate cancer	1.78e-05	0.000144	CcSEcCtD
Carvedilol—Hypersensitivity—Docetaxel—prostate cancer	1.78e-05	0.000144	CcSEcCtD
Carvedilol—Muscle spasms—Doxorubicin—prostate cancer	1.77e-05	0.000143	CcSEcCtD
Carvedilol—Palpitations—Epirubicin—prostate cancer	1.76e-05	0.000143	CcSEcCtD
Carvedilol—Loss of consciousness—Epirubicin—prostate cancer	1.75e-05	0.000142	CcSEcCtD
Carvedilol—Cough—Epirubicin—prostate cancer	1.74e-05	0.000141	CcSEcCtD
Carvedilol—Vision blurred—Doxorubicin—prostate cancer	1.74e-05	0.000141	CcSEcCtD
Carvedilol—Asthenia—Docetaxel—prostate cancer	1.73e-05	0.00014	CcSEcCtD
Carvedilol—Convulsion—Epirubicin—prostate cancer	1.73e-05	0.00014	CcSEcCtD
Carvedilol—Nausea—Etoposide—prostate cancer	1.72e-05	0.000139	CcSEcCtD
Carvedilol—Hypertension—Epirubicin—prostate cancer	1.72e-05	0.000139	CcSEcCtD
Carvedilol—Hypersensitivity—Capecitabine—prostate cancer	1.72e-05	0.000139	CcSEcCtD
Carvedilol—Feeling abnormal—Prednisone—prostate cancer	1.71e-05	0.000139	CcSEcCtD
Carvedilol—Ill-defined disorder—Doxorubicin—prostate cancer	1.71e-05	0.000138	CcSEcCtD
Carvedilol—Pruritus—Docetaxel—prostate cancer	1.71e-05	0.000138	CcSEcCtD
Carvedilol—Anaemia—Doxorubicin—prostate cancer	1.71e-05	0.000138	CcSEcCtD
Carvedilol—Gastrointestinal pain—Prednisone—prostate cancer	1.7e-05	0.000138	CcSEcCtD
Carvedilol—Chest pain—Epirubicin—prostate cancer	1.7e-05	0.000137	CcSEcCtD
Carvedilol—Arthralgia—Epirubicin—prostate cancer	1.7e-05	0.000137	CcSEcCtD
Carvedilol—Myalgia—Epirubicin—prostate cancer	1.7e-05	0.000137	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.69e-05	0.000136	CcSEcCtD
Carvedilol—Discomfort—Epirubicin—prostate cancer	1.68e-05	0.000136	CcSEcCtD
Carvedilol—Asthenia—Capecitabine—prostate cancer	1.68e-05	0.000136	CcSEcCtD
Carvedilol—Malaise—Doxorubicin—prostate cancer	1.66e-05	0.000135	CcSEcCtD
Carvedilol—Dry mouth—Epirubicin—prostate cancer	1.66e-05	0.000134	CcSEcCtD
Carvedilol—Vertigo—Doxorubicin—prostate cancer	1.66e-05	0.000134	CcSEcCtD
Carvedilol—Syncope—Doxorubicin—prostate cancer	1.65e-05	0.000134	CcSEcCtD
Carvedilol—Urticaria—Prednisone—prostate cancer	1.65e-05	0.000134	CcSEcCtD
Carvedilol—Pruritus—Capecitabine—prostate cancer	1.65e-05	0.000134	CcSEcCtD
Carvedilol—Leukopenia—Doxorubicin—prostate cancer	1.65e-05	0.000134	CcSEcCtD
Carvedilol—Diarrhoea—Docetaxel—prostate cancer	1.65e-05	0.000134	CcSEcCtD
Carvedilol—Abdominal pain—Prednisone—prostate cancer	1.65e-05	0.000133	CcSEcCtD
Carvedilol—Body temperature increased—Prednisone—prostate cancer	1.65e-05	0.000133	CcSEcCtD
Carvedilol—Confusional state—Epirubicin—prostate cancer	1.64e-05	0.000133	CcSEcCtD
Carvedilol—Palpitations—Doxorubicin—prostate cancer	1.63e-05	0.000132	CcSEcCtD
Carvedilol—Anaphylactic shock—Epirubicin—prostate cancer	1.63e-05	0.000132	CcSEcCtD
Carvedilol—Oedema—Epirubicin—prostate cancer	1.63e-05	0.000132	CcSEcCtD
Carvedilol—Loss of consciousness—Doxorubicin—prostate cancer	1.62e-05	0.000131	CcSEcCtD
Carvedilol—Infection—Epirubicin—prostate cancer	1.62e-05	0.000131	CcSEcCtD
Carvedilol—Cough—Doxorubicin—prostate cancer	1.61e-05	0.00013	CcSEcCtD
Carvedilol—Shock—Epirubicin—prostate cancer	1.6e-05	0.000129	CcSEcCtD
Carvedilol—Convulsion—Doxorubicin—prostate cancer	1.6e-05	0.000129	CcSEcCtD
Carvedilol—Diarrhoea—Capecitabine—prostate cancer	1.6e-05	0.000129	CcSEcCtD
Carvedilol—Dizziness—Docetaxel—prostate cancer	1.6e-05	0.000129	CcSEcCtD
Carvedilol—Thrombocytopenia—Epirubicin—prostate cancer	1.59e-05	0.000129	CcSEcCtD
Carvedilol—Hypertension—Doxorubicin—prostate cancer	1.59e-05	0.000129	CcSEcCtD
Carvedilol—Tachycardia—Epirubicin—prostate cancer	1.59e-05	0.000128	CcSEcCtD
Carvedilol—Skin disorder—Epirubicin—prostate cancer	1.58e-05	0.000128	CcSEcCtD
Carvedilol—Hyperhidrosis—Epirubicin—prostate cancer	1.57e-05	0.000127	CcSEcCtD
Carvedilol—Arthralgia—Doxorubicin—prostate cancer	1.57e-05	0.000127	CcSEcCtD
Carvedilol—Myalgia—Doxorubicin—prostate cancer	1.57e-05	0.000127	CcSEcCtD
Carvedilol—Chest pain—Doxorubicin—prostate cancer	1.57e-05	0.000127	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.56e-05	0.000126	CcSEcCtD
Carvedilol—Discomfort—Doxorubicin—prostate cancer	1.55e-05	0.000126	CcSEcCtD
Carvedilol—Anorexia—Epirubicin—prostate cancer	1.55e-05	0.000125	CcSEcCtD
Carvedilol—Dizziness—Capecitabine—prostate cancer	1.55e-05	0.000125	CcSEcCtD
Carvedilol—Dry mouth—Doxorubicin—prostate cancer	1.54e-05	0.000124	CcSEcCtD
Carvedilol—Vomiting—Docetaxel—prostate cancer	1.53e-05	0.000124	CcSEcCtD
Carvedilol—Hypersensitivity—Prednisone—prostate cancer	1.53e-05	0.000124	CcSEcCtD
Carvedilol—Rash—Docetaxel—prostate cancer	1.52e-05	0.000123	CcSEcCtD
Carvedilol—Hypotension—Epirubicin—prostate cancer	1.52e-05	0.000123	CcSEcCtD
Carvedilol—Dermatitis—Docetaxel—prostate cancer	1.52e-05	0.000123	CcSEcCtD
Carvedilol—Confusional state—Doxorubicin—prostate cancer	1.52e-05	0.000123	CcSEcCtD
Carvedilol—Headache—Docetaxel—prostate cancer	1.51e-05	0.000122	CcSEcCtD
Carvedilol—Oedema—Doxorubicin—prostate cancer	1.51e-05	0.000122	CcSEcCtD
Carvedilol—Anaphylactic shock—Doxorubicin—prostate cancer	1.51e-05	0.000122	CcSEcCtD
Carvedilol—Infection—Doxorubicin—prostate cancer	1.5e-05	0.000121	CcSEcCtD
Carvedilol—Asthenia—Prednisone—prostate cancer	1.49e-05	0.000121	CcSEcCtD
Carvedilol—Vomiting—Capecitabine—prostate cancer	1.49e-05	0.00012	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.48e-05	0.00012	CcSEcCtD
Carvedilol—Shock—Doxorubicin—prostate cancer	1.48e-05	0.00012	CcSEcCtD
Carvedilol—Thrombocytopenia—Doxorubicin—prostate cancer	1.47e-05	0.000119	CcSEcCtD
Carvedilol—Rash—Capecitabine—prostate cancer	1.47e-05	0.000119	CcSEcCtD
Carvedilol—Pruritus—Prednisone—prostate cancer	1.47e-05	0.000119	CcSEcCtD
Carvedilol—Insomnia—Epirubicin—prostate cancer	1.47e-05	0.000119	CcSEcCtD
Carvedilol—Dermatitis—Capecitabine—prostate cancer	1.47e-05	0.000119	CcSEcCtD
Carvedilol—Tachycardia—Doxorubicin—prostate cancer	1.47e-05	0.000119	CcSEcCtD
Carvedilol—Headache—Capecitabine—prostate cancer	1.46e-05	0.000118	CcSEcCtD
Carvedilol—Skin disorder—Doxorubicin—prostate cancer	1.46e-05	0.000118	CcSEcCtD
Carvedilol—Paraesthesia—Epirubicin—prostate cancer	1.46e-05	0.000118	CcSEcCtD
Carvedilol—Hyperhidrosis—Doxorubicin—prostate cancer	1.46e-05	0.000118	CcSEcCtD
Carvedilol—Dyspnoea—Epirubicin—prostate cancer	1.45e-05	0.000117	CcSEcCtD
Carvedilol—Somnolence—Epirubicin—prostate cancer	1.45e-05	0.000117	CcSEcCtD
Carvedilol—Anorexia—Doxorubicin—prostate cancer	1.44e-05	0.000116	CcSEcCtD
Carvedilol—Nausea—Docetaxel—prostate cancer	1.43e-05	0.000116	CcSEcCtD
Carvedilol—Dyspepsia—Epirubicin—prostate cancer	1.43e-05	0.000116	CcSEcCtD
Carvedilol—Diarrhoea—Prednisone—prostate cancer	1.42e-05	0.000115	CcSEcCtD
Carvedilol—Decreased appetite—Epirubicin—prostate cancer	1.41e-05	0.000114	CcSEcCtD
Carvedilol—Hypotension—Doxorubicin—prostate cancer	1.41e-05	0.000114	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Epirubicin—prostate cancer	1.41e-05	0.000114	CcSEcCtD
Carvedilol—Fatigue—Epirubicin—prostate cancer	1.4e-05	0.000113	CcSEcCtD
Carvedilol—Pain—Epirubicin—prostate cancer	1.39e-05	0.000113	CcSEcCtD
Carvedilol—Constipation—Epirubicin—prostate cancer	1.39e-05	0.000113	CcSEcCtD
Carvedilol—Nausea—Capecitabine—prostate cancer	1.39e-05	0.000112	CcSEcCtD
Carvedilol—Dizziness—Prednisone—prostate cancer	1.38e-05	0.000111	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.37e-05	0.000111	CcSEcCtD
Carvedilol—Insomnia—Doxorubicin—prostate cancer	1.36e-05	0.00011	CcSEcCtD
Carvedilol—Paraesthesia—Doxorubicin—prostate cancer	1.35e-05	0.000109	CcSEcCtD
Carvedilol—Dyspnoea—Doxorubicin—prostate cancer	1.34e-05	0.000109	CcSEcCtD
Carvedilol—Feeling abnormal—Epirubicin—prostate cancer	1.34e-05	0.000108	CcSEcCtD
Carvedilol—Somnolence—Doxorubicin—prostate cancer	1.34e-05	0.000108	CcSEcCtD
Carvedilol—Gastrointestinal pain—Epirubicin—prostate cancer	1.33e-05	0.000108	CcSEcCtD
Carvedilol—Dyspepsia—Doxorubicin—prostate cancer	1.33e-05	0.000107	CcSEcCtD
Carvedilol—Vomiting—Prednisone—prostate cancer	1.32e-05	0.000107	CcSEcCtD
Carvedilol—Rash—Prednisone—prostate cancer	1.31e-05	0.000106	CcSEcCtD
Carvedilol—Dermatitis—Prednisone—prostate cancer	1.31e-05	0.000106	CcSEcCtD
Carvedilol—Decreased appetite—Doxorubicin—prostate cancer	1.31e-05	0.000106	CcSEcCtD
Carvedilol—Headache—Prednisone—prostate cancer	1.3e-05	0.000105	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.3e-05	0.000105	CcSEcCtD
Carvedilol—Fatigue—Doxorubicin—prostate cancer	1.3e-05	0.000105	CcSEcCtD
Carvedilol—Urticaria—Epirubicin—prostate cancer	1.29e-05	0.000105	CcSEcCtD
Carvedilol—Constipation—Doxorubicin—prostate cancer	1.29e-05	0.000104	CcSEcCtD
Carvedilol—Pain—Doxorubicin—prostate cancer	1.29e-05	0.000104	CcSEcCtD
Carvedilol—Body temperature increased—Epirubicin—prostate cancer	1.29e-05	0.000104	CcSEcCtD
Carvedilol—Abdominal pain—Epirubicin—prostate cancer	1.29e-05	0.000104	CcSEcCtD
Carvedilol—Feeling abnormal—Doxorubicin—prostate cancer	1.24e-05	0.0001	CcSEcCtD
Carvedilol—Nausea—Prednisone—prostate cancer	1.24e-05	0.0001	CcSEcCtD
Carvedilol—Gastrointestinal pain—Doxorubicin—prostate cancer	1.23e-05	9.96e-05	CcSEcCtD
Carvedilol—Hypersensitivity—Epirubicin—prostate cancer	1.2e-05	9.7e-05	CcSEcCtD
Carvedilol—Urticaria—Doxorubicin—prostate cancer	1.2e-05	9.68e-05	CcSEcCtD
Carvedilol—Abdominal pain—Doxorubicin—prostate cancer	1.19e-05	9.63e-05	CcSEcCtD
Carvedilol—Body temperature increased—Doxorubicin—prostate cancer	1.19e-05	9.63e-05	CcSEcCtD
Carvedilol—Asthenia—Epirubicin—prostate cancer	1.17e-05	9.44e-05	CcSEcCtD
Carvedilol—Pruritus—Epirubicin—prostate cancer	1.15e-05	9.31e-05	CcSEcCtD
Carvedilol—Diarrhoea—Epirubicin—prostate cancer	1.11e-05	9.01e-05	CcSEcCtD
Carvedilol—Hypersensitivity—Doxorubicin—prostate cancer	1.11e-05	8.97e-05	CcSEcCtD
Carvedilol—Asthenia—Doxorubicin—prostate cancer	1.08e-05	8.74e-05	CcSEcCtD
Carvedilol—Dizziness—Epirubicin—prostate cancer	1.08e-05	8.7e-05	CcSEcCtD
Carvedilol—Pruritus—Doxorubicin—prostate cancer	1.07e-05	8.62e-05	CcSEcCtD
Carvedilol—Vomiting—Epirubicin—prostate cancer	1.03e-05	8.37e-05	CcSEcCtD
Carvedilol—Diarrhoea—Doxorubicin—prostate cancer	1.03e-05	8.33e-05	CcSEcCtD
Carvedilol—Rash—Epirubicin—prostate cancer	1.03e-05	8.3e-05	CcSEcCtD
Carvedilol—Dermatitis—Epirubicin—prostate cancer	1.03e-05	8.29e-05	CcSEcCtD
Carvedilol—Headache—Epirubicin—prostate cancer	1.02e-05	8.25e-05	CcSEcCtD
Carvedilol—Dizziness—Doxorubicin—prostate cancer	9.96e-06	8.05e-05	CcSEcCtD
Carvedilol—Nausea—Epirubicin—prostate cancer	9.67e-06	7.82e-05	CcSEcCtD
Carvedilol—Vomiting—Doxorubicin—prostate cancer	9.58e-06	7.74e-05	CcSEcCtD
Carvedilol—Rash—Doxorubicin—prostate cancer	9.5e-06	7.68e-05	CcSEcCtD
Carvedilol—Dermatitis—Doxorubicin—prostate cancer	9.49e-06	7.67e-05	CcSEcCtD
Carvedilol—Headache—Doxorubicin—prostate cancer	9.43e-06	7.63e-05	CcSEcCtD
Carvedilol—Nausea—Doxorubicin—prostate cancer	8.95e-06	7.23e-05	CcSEcCtD
Carvedilol—ADRB2—Signaling Pathways—PTEN—prostate cancer	5.33e-07	4.86e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	5.33e-07	4.85e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—NOS3—prostate cancer	5.32e-07	4.85e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	5.32e-07	4.84e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP1B1—prostate cancer	5.31e-07	4.84e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CAV1—prostate cancer	5.29e-07	4.82e-06	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—AKT1—prostate cancer	5.29e-07	4.82e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CASP3—prostate cancer	5.28e-07	4.81e-06	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—AKT1—prostate cancer	5.28e-07	4.81e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2—prostate cancer	5.28e-07	4.81e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—AKT1—prostate cancer	5.27e-07	4.8e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	5.27e-07	4.8e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL6—prostate cancer	5.25e-07	4.78e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CAV1—prostate cancer	5.25e-07	4.78e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MDM2—prostate cancer	5.25e-07	4.78e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCND1—prostate cancer	5.23e-07	4.76e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CYP1A1—prostate cancer	5.22e-07	4.75e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—FGF2—prostate cancer	5.21e-07	4.75e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CB—prostate cancer	5.21e-07	4.74e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	5.2e-07	4.74e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EP300—prostate cancer	5.2e-07	4.74e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	5.18e-07	4.72e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ERCC2—prostate cancer	5.17e-07	4.71e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	5.17e-07	4.71e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—prostate cancer	5.16e-07	4.7e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EP300—prostate cancer	5.15e-07	4.69e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GGT1—prostate cancer	5.14e-07	4.69e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCND1—prostate cancer	5.14e-07	4.69e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NOS3—prostate cancer	5.14e-07	4.68e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CG—prostate cancer	5.12e-07	4.66e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	5.1e-07	4.65e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	5.09e-07	4.64e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EP300—prostate cancer	5.08e-07	4.63e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—prostate cancer	5.07e-07	4.62e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NCOA1—prostate cancer	5.07e-07	4.62e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	5.06e-07	4.61e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—SRC—prostate cancer	5.05e-07	4.61e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PTEN—prostate cancer	5.04e-07	4.6e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	5.01e-07	4.57e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—SRC—prostate cancer	5.01e-07	4.56e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—prostate cancer	4.99e-07	4.55e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.99e-07	4.55e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—JAK2—prostate cancer	4.99e-07	4.55e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	4.98e-07	4.53e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MYC—prostate cancer	4.97e-07	4.53e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTEN—prostate cancer	4.96e-07	4.52e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TGFB1—prostate cancer	4.96e-07	4.52e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—SRC—prostate cancer	4.94e-07	4.5e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	4.92e-07	4.49e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	4.92e-07	4.48e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CB—prostate cancer	4.91e-07	4.47e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	4.9e-07	4.47e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTEN—prostate cancer	4.9e-07	4.46e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	4.89e-07	4.46e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	4.88e-07	4.44e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STAT3—prostate cancer	4.87e-07	4.44e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MDM2—prostate cancer	4.87e-07	4.44e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—prostate cancer	4.86e-07	4.43e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—MTHFR—prostate cancer	4.86e-07	4.43e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—prostate cancer	4.86e-07	4.43e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—INS—prostate cancer	4.84e-07	4.41e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	4.84e-07	4.41e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STAT3—prostate cancer	4.83e-07	4.4e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CG—prostate cancer	4.82e-07	4.39e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—RXRA—prostate cancer	4.82e-07	4.39e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	4.82e-07	4.39e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EP300—prostate cancer	4.81e-07	4.38e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	4.8e-07	4.38e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	4.79e-07	4.36e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CG—prostate cancer	4.78e-07	4.36e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PPARA—prostate cancer	4.77e-07	4.35e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STAT3—prostate cancer	4.77e-07	4.34e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CREBBP—prostate cancer	4.74e-07	4.32e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	4.74e-07	4.32e-06	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	4.74e-07	4.32e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EP300—prostate cancer	4.73e-07	4.31e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CASP3—prostate cancer	4.69e-07	4.28e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2—prostate cancer	4.69e-07	4.27e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SRC—prostate cancer	4.68e-07	4.26e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—EP300—prostate cancer	4.67e-07	4.26e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL6—prostate cancer	4.66e-07	4.25e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—COMT—prostate cancer	4.64e-07	4.23e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTP1—prostate cancer	4.62e-07	4.21e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SRC—prostate cancer	4.6e-07	4.19e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—prostate cancer	4.59e-07	4.18e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCND1—prostate cancer	4.57e-07	4.16e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—INS—prostate cancer	4.56e-07	4.16e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	4.56e-07	4.15e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	4.56e-07	4.15e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ITPR1—prostate cancer	4.55e-07	4.14e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MYC—prostate cancer	4.53e-07	4.13e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—INS—prostate cancer	4.53e-07	4.12e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	4.52e-07	4.12e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	4.52e-07	4.12e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STAT3—prostate cancer	4.51e-07	4.11e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTEN—prostate cancer	4.5e-07	4.1e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CD—prostate cancer	4.5e-07	4.1e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MYC—prostate cancer	4.49e-07	4.09e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CAV1—prostate cancer	4.49e-07	4.09e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	4.48e-07	4.09e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	4.48e-07	4.08e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CREBBP—prostate cancer	4.47e-07	4.07e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	4.45e-07	4.05e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STAT3—prostate cancer	4.44e-07	4.05e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—prostate cancer	4.44e-07	4.04e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CREBBP—prostate cancer	4.43e-07	4.04e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MYC—prostate cancer	4.43e-07	4.04e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—prostate cancer	4.43e-07	4.04e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	4.42e-07	4.03e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	4.42e-07	4.03e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTEN—prostate cancer	4.41e-07	4.02e-06	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	4.4e-07	4.01e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—prostate cancer	4.39e-07	4e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CASP3—prostate cancer	4.36e-07	3.97e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2—prostate cancer	4.35e-07	3.97e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—prostate cancer	4.33e-07	3.95e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL6—prostate cancer	4.33e-07	3.95e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	4.3e-07	3.92e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—TYMS—prostate cancer	4.3e-07	3.91e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—EP300—prostate cancer	4.29e-07	3.91e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.28e-07	3.9e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PIK3CA—prostate cancer	4.26e-07	3.88e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—NOS3—prostate cancer	4.25e-07	3.87e-06	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PIK3CA—prostate cancer	4.25e-07	3.87e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTM1—prostate cancer	4.25e-07	3.87e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCND1—prostate cancer	4.25e-07	3.87e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTEN—prostate cancer	4.24e-07	3.87e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CD—prostate cancer	4.24e-07	3.86e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	4.22e-07	3.84e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EP300—prostate cancer	4.21e-07	3.83e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	4.2e-07	3.83e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CD—prostate cancer	4.2e-07	3.83e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MYC—prostate cancer	4.19e-07	3.82e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—prostate cancer	4.19e-07	3.81e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	4.18e-07	3.81e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—LPL—prostate cancer	4.17e-07	3.8e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—prostate cancer	4.15e-07	3.78e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MYC—prostate cancer	4.13e-07	3.76e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—prostate cancer	4.12e-07	3.76e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	4.12e-07	3.75e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	4.11e-07	3.74e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—prostate cancer	4.1e-07	3.74e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTEN—prostate cancer	4.1e-07	3.73e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—prostate cancer	4.09e-07	3.73e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SRC—prostate cancer	4.09e-07	3.73e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CG—prostate cancer	4.09e-07	3.72e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—prostate cancer	4.08e-07	3.72e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—EP300—prostate cancer	4.05e-07	3.69e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—prostate cancer	4.04e-07	3.68e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP1A1—prostate cancer	4.03e-07	3.67e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—NOS3—prostate cancer	4e-07	3.65e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	4e-07	3.64e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ERCC2—prostate cancer	3.99e-07	3.64e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	3.98e-07	3.63e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—NOS3—prostate cancer	3.97e-07	3.62e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STAT3—prostate cancer	3.94e-07	3.59e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CB—prostate cancer	3.92e-07	3.57e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EP300—prostate cancer	3.91e-07	3.56e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—prostate cancer	3.89e-07	3.54e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—prostate cancer	3.87e-07	3.53e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—INS—prostate cancer	3.87e-07	3.52e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	3.84e-07	3.5e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—prostate cancer	3.81e-07	3.47e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	3.81e-07	3.47e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SRC—prostate cancer	3.8e-07	3.46e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CREBBP—prostate cancer	3.79e-07	3.45e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	3.76e-07	3.43e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—MTHFR—prostate cancer	3.75e-07	3.42e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL6—prostate cancer	3.74e-07	3.4e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—prostate cancer	3.72e-07	3.39e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	3.7e-07	3.37e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CB—prostate cancer	3.7e-07	3.37e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—prostate cancer	3.69e-07	3.36e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PPARA—prostate cancer	3.68e-07	3.35e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MYC—prostate cancer	3.66e-07	3.34e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STAT3—prostate cancer	3.66e-07	3.34e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CB—prostate cancer	3.66e-07	3.34e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—prostate cancer	3.66e-07	3.34e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	3.66e-07	3.33e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—prostate cancer	3.64e-07	3.32e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—prostate cancer	3.63e-07	3.31e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CD—prostate cancer	3.59e-07	3.27e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—prostate cancer	3.58e-07	3.27e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	3.56e-07	3.24e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	3.5e-07	3.19e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—AKT1—prostate cancer	3.48e-07	3.17e-06	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—AKT1—prostate cancer	3.47e-07	3.16e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CAV1—prostate cancer	3.46e-07	3.15e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CA—prostate cancer	3.46e-07	3.15e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AKT1—prostate cancer	3.45e-07	3.14e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—prostate cancer	3.44e-07	3.14e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MYC—prostate cancer	3.41e-07	3.1e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL6—prostate cancer	3.4e-07	3.1e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	3.4e-07	3.09e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—NOS3—prostate cancer	3.39e-07	3.09e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTEN—prostate cancer	3.39e-07	3.09e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—prostate cancer	3.39e-07	3.09e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—prostate cancer	3.39e-07	3.09e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL6—prostate cancer	3.37e-07	3.07e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL6—prostate cancer	3.33e-07	3.03e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—prostate cancer	3.33e-07	3.03e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—EP300—prostate cancer	3.23e-07	2.94e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTEN—prostate cancer	3.19e-07	2.91e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CA—prostate cancer	3.17e-07	2.89e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTEN—prostate cancer	3.17e-07	2.88e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.15e-07	2.87e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL6—prostate cancer	3.15e-07	2.87e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—prostate cancer	3.15e-07	2.87e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AKT1—prostate cancer	3.14e-07	2.86e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CB—prostate cancer	3.13e-07	2.85e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AKT1—prostate cancer	3.11e-07	2.84e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	3.11e-07	2.83e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—prostate cancer	3.1e-07	2.83e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL6—prostate cancer	3.1e-07	2.83e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AKT1—prostate cancer	3.07e-07	2.8e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—EP300—prostate cancer	3.05e-07	2.77e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—EP300—prostate cancer	3.02e-07	2.75e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—prostate cancer	3.01e-07	2.74e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CA—prostate cancer	2.99e-07	2.73e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—INS—prostate cancer	2.98e-07	2.72e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CREBBP—prostate cancer	2.92e-07	2.66e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AKT1—prostate cancer	2.91e-07	2.65e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	2.89e-07	2.63e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AKT1—prostate cancer	2.86e-07	2.61e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—AKT1—prostate cancer	2.82e-07	2.57e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—prostate cancer	2.8e-07	2.55e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.77e-07	2.53e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL6—prostate cancer	2.75e-07	2.51e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTEN—prostate cancer	2.71e-07	2.46e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NOS3—prostate cancer	2.62e-07	2.38e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—AKT1—prostate cancer	2.59e-07	2.36e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—EP300—prostate cancer	2.58e-07	2.35e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL6—prostate cancer	2.56e-07	2.33e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AKT1—prostate cancer	2.54e-07	2.32e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—AKT1—prostate cancer	2.44e-07	2.23e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.42e-07	2.2e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—prostate cancer	2.39e-07	2.18e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CA—prostate cancer	2.39e-07	2.18e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AKT1—prostate cancer	2.36e-07	2.15e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CA—prostate cancer	2.25e-07	2.05e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CA—prostate cancer	2.23e-07	2.03e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTEN—prostate cancer	2.09e-07	1.9e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—EP300—prostate cancer	1.99e-07	1.81e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—AKT1—prostate cancer	1.95e-07	1.78e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CA—prostate cancer	1.91e-07	1.74e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—AKT1—prostate cancer	1.84e-07	1.68e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—AKT1—prostate cancer	1.82e-07	1.66e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—AKT1—prostate cancer	1.56e-07	1.42e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.47e-07	1.34e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AKT1—prostate cancer	1.2e-07	1.1e-06	CbGpPWpGaD
